Background-Matrix metalloproteinases (MMPs) play a key role in cardiovascular disease, in particular aneurysm formation and plaque rupture. Surprisingly, little is known about MMP substrates in the vasculature. Methods and Results-We used a proteomics approach to identify vascular substrates for 3 MMPs, 1 of each of the 3 major classes of MMPs: Human arteries were incubated with MMP-3 (a member of stromelysins), MMP-9 (considered a gelatinase), and MMP-14 (considered a member of the collagenases and of the membrane-bound MMPs). Candidate substrates were identified by mass spectrometry based on increased release from the arterial tissue on digestion, spectral evidence for proteolytic degradation after gel separation, and identification of nontryptic cleavage sites. Using this approach, novel candidates were identified, including extracellular matrix proteins associated with the basement membrane, elastic fibers (emilin-1), and other extracellular proteins (periostin, tenascin-X). Seventy-four nontryptic cleavage sites were detected, many of which were shared among different MMPs. The proteomics findings were validated by immunoblotting and by digesting recombinant/purified proteins with exogenous MMPs. As proof-of-principle, results were related to in vivo pathology by searching for corresponding degradation products in human aortic tissue with different levels of endogenous MMP-9. Conclusions-The application of proteomics to identify MMP targets is a new frontier in cardiovascular research. Our current classification of MMPs based on few substrates is an oversimplification of a complex area of biology. This study provides a more comprehensive assessment of potential MMP substrates in the vasculature and represents a valuable resource for future investigations. (Circ Cardiovasc Genet. 2013;6:106-117.)
M atrix metalloproteinases (MMPs) are endopeptidases that require zinc as a cofactor. Increased MMP activity is thought to be associated with rupture of vulnerable atherosclerotic plaques and aneurysm formation. Excessive expression of MMPs by macrophages and smooth muscle cells likely contributes to weakening of the vascular wall via their capacity to cleave the extracellular matrix (ECM). Thus far, the role of MMPs in atherosclerosis has been mainly investigated using transgenic or knock-out mice, but the results can be confusing. 1 For example, MMP inhibition by genetic deletion of one of the MMP genes or by a pharmacological intervention using an MMP inhibitor decreased aneurysm and neointima formation. 1 Yet overexpression of MMP-1 resulted in a decreased plaque size, inhibition of MMP-3 led to an increase in plaque size and plaque progression, and a broad range of MMP inhibitors had no effect on plaque size. Thus, interventions aimed at altering MMP expression/activity revealed the complexity of the regulation of ECM turnover and that actions of certain members of the MMP family may be redundant or compensatory in nature.
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Although the literature on MMPs and cardiovascular phenotypes in animal models is extensive, 1 their vascular substrates have not been comprehensively characterized. MMPs tend to be grouped into interstitial collagenases (MMPs-1, -8, -13, -14) that cleave fibrillar collagens, gelatinases (MMPs-2 and -9) that efficiently cleave denatured collagen (ie, gelatin), and stromelysins (MMPs-3, -7, -10, -11) that have a broad specificity but do not cleave intact fibrillar collagen. 2 In this study, we attempt to gain a more comprehensive picture by using a proteomics approach. We identify candidate substrates for 3 MMPs, 1 from each of the 3 major classes of MMPs: MMP-3, MMP-9, and MMP-14. All 3 MMPs are implicated in cardiovascular pathologies: MMP-14 (a membrane-bound MMP) is induced in macrophages by oxidized lipoproteins and degrades a broad range of substrates in the pericellular regions including other MMPs. 3 Similarly, macrophages as well as vascular smooth muscle cells secrete MMP-9 after inflammatory activation. 4 Levels of MMP-9 are increased in atherosclerotic plaques with histological features of vulnerability to rupture. 5 MMP-3 as well as other stromelysins are considered to display the broadest substrate specificity. Functional genetic polymorphisms present in the MMP-3 promoters have been associated with atherosclerosis progression and the risk of abdominal aortic aneurysms as reviewed elsewhere. 1
Methods

Source of Tissue
Human radial arteries were obtained from 3 men >50 years of age undergoing coronary bypass surgery. Four human aortas were obtained from patients without connective tissue disorder (1 woman and 3 men 20-55 years of age) on aortotomy performed during routine aortic valve replacement from positions of the ascending aorta. The study was approved by St. George's Hospital and the National Research Ethics Service Committee, London, Wandsworth. Patients gave written informed consent.
Digestion With MMPs
Before extraction, the tissue was partially thawed and weighed. Approximately 120 mg of tissue were first washed with ice-cold PBS (Lonza, Belgium) containing protease and phosphatase inhibitor (Sigma-Aldrich, St. Louis, MO). The tissue was diced into 5 pieces of ≈20 mg and washed 3 times with PBS before a final wash with 1 mL MMP reaction buffer (10 mmol/L CaCl 2 , 120 mmol/L NaCl, 50 mmol/L Tris, pH 9.0, containing 10 μL protease and phosphatase inhibitors). For digestion, each sample (n=5) was incubated in MMP reaction buffer at 37°C. The volume of the buffer was adjusted to 10:1 of the tissue weight and included 3 μL of protease inhibitor per sample. One sample was used as control to monitor background MMP activity and incubated only in buffer with protease inhibitor (for inhibition of endogenous proteases other than MMPs). A second control was incubated in buffer with protease inhibitor plus 25 mmol/L EDTA (Sigma-Aldrich) to ensure inhibition of MMPs. The 3 remaining samples were incubated with 10 μg/mL MMP-3, MMP-9 (Calbiochem, Darmstadt, Germany), or MMP-14 (R&D Systems, Minneapolis, MN) at 100 ng MMP/mg arterial tissue. MMP-14 was activated with furin (R&D Systems, Minneapolis, MN) according to the manufacturer's protocol. After 28-hour incubation with radial arterial tissue, the supernatant was transferred in new tubes, and released proteins were deglycosylated in deglycosylation buffer (150 mmol/L NaCl, 50 mmol/L sodium acetate, 25 mmol/L EDTA, pH 6.8) containing chondroitinase ABC from Proteus vulgaris and keratanase from Pseudomonas sp. (both Sigma-Aldrich). After an overnight incubation at 37°C, samples were concentrated by vacuum centrifugation for 30 minutes, and the protein concentration was estimated by ultraviolet absorbance at 280 nm using a NanoDrop ND-1000 (Thermo Scientific, Barrington, IL).
SDS-Page
4x sample buffer (100 mmol/L Tris, pH 6.8, containing 40% glycerol, 0.2% SDS, 2% β-mercaptoethanol, 0.02% bromophenol blue) was added to 45 µg of protein. After boiling (5 minutes at 96°C), samples were separated together with a protein standard (All Blue, Precision, Bio-Rad Laboratories, Hercules, CA) on Bis-Tris 4% to 12% polyacrylamide gradient gels (NuPage, Life-Technologies, Grand Island, NY).
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Gels were stained with Coomasie G-250. Sixteen bands were excised per lane, destained, reduced, alkylated, and digested with sequencing grade modified trypsin (Promega, Madison, WI) using an Investigator ProGest (Genomic Solutions, Bath, United Kingdom) robotic digestion system. Peptides were analyzed by LC-MS/MS as described. 6, 7 Tryptic peptides were separated by reverse phase chromatography (Acclaim PepMap100 C18, 75 µm × 15 cm) on a nanoflow LC system (Ultimate3000, Dionex, Madison, WI) equipped with a trap column (Acclaim PepMap100 C18, 300 µm × 5 mm). The chromatographic separation was performed with a mobile phase of high performance liquid chromatography grade water containing 2% acetonitrile and 0.1% formic aid (eluent A) and a solvent phase of acetonitrile containing 10% high performance liquid chromatography water (Thermo Fisher Scientific, Waltham, MA) and 0.1% formic acid (eluent B) with a 90-minute gradient (10% to 25%B in 55 minutes, 55% to 60%B in 5 minutes, 90%B for 8 minutes, 90% to 2%B in 22 minutes) at a flow rate of 300 nL/min. The column was coupled to an LTQ OrbitrapXL mass spectrometer (Thermo Fisher Scientific) with a nanospray source (Picoview, Agilent Technologies, Santa Barbara, CA). The mass spectrometry acquisition involved 1 full MS scan over a mass range encompassing 450-1600 Da, followed by data-dependent collision-induced dissociation MS/MS scans of the 6 most intense ions detected in the full scan, with dynamic exclusion enabled and rejection of singly charged ions.
Data Analysis
Mascot Daemon (Matrix Science, London, United Kingdom; version 2.3.0) was used to extract each raw data file into a set of DTA files, which were merged into MGF files. These files were searched against a subset (human, 20 266 entries) of the UniProtKB/Swiss-Prot database (SwissProt_57.15) using Mascot (Matrix Science, London, United Kingdom; version 2.3.01). A mass tolerance of 10 ppm for precursor ion scans and a mass tolerance of 0.8 Da for the product ion scans were used. Semitrypsin with up to 2 missed cleavage sites was chosen as enzymatic cleavage to identify nontryptic MMP cleavage sites. Iodoacetamide derivative of cysteine was specified as a fixed modification, and hydroxylation of proline and lysine and oxidation of methionine were specified as variable modifications. Scaffold (version Scaffold_3_00_02, Proteome Software Inc., Portland, OR) was used to calculate the spectral counts and validate MS/MS-based peptide and protein identifications: peptide identifications were accepted if they could be established at >95.0% probability, and protein identifications were accepted if they could be established at >99.0% probability with at least 2 independent identified peptides and a mass accuracy of ≤10 ppm of the precursor ion.
Western Blotting
Proteins were transferred to nitrocellulose (GE Healthcare, Waukesha, WI). Membranes were blocked in 5% fat-free milk powder in PBS and probed for 16 hours at 4°C with antibodies purchased from Santa Cruz Biotechnology (Santa Cruz, CA) or Abcam (Cambridge, United Kingdom): tenascin-C (ab6393), periostin (sc-67233), galectin-1 (ab38328), fibronectin (sc-56391), and tenascin-X (sc-25717). Primary antibodies were used at a 1:500 dilution in 5% bovine serum albumin (Sigma-Aldrich). Peroxidase-conjugated antibodies (Dako, Glostrup, Denmark) were used at a 1:1500 dilution. Using enhanced chemiluminescence (ECL; GE Healthcare), films were developed on a Xograph processor (Tetbury, United Kingdom).
Recombinant Proteins
Ten micrograms of periostin (both R&D Systems), fibronectin (Sigma), and tenascin-C (Millipore, Billerica, MA) were incubated with MMP-3, MMP-9, and MMP-14 at a molar protein/MMP ratio of 10:1 for 16 hours at 37°C. Controls were incubated without MMPs. Reactions were terminated by addition of EDTA (final concentration 25 mmol/L). Periostin, fibronectin, and tenascin-C were analyzed by SDS-PAGE using 3-(N-morpholino)propanesulfonic acid running buffer and stained with Colloidal Blue (Life-Technologies). In addition, all recombinant proteins were reduced, alkylated, and digested with trypsin at 37°C overnight and analyzed directly without prior gel separation by LC-MS/MS. February 2013
Statistical Analysis
The differential expression analysis was performed using the Qspec method as described by Choi et al. 8 Qspec uses a model based on a hierarchical Bayes estimation of generalized linear mixed effects model to calculate the differential expression. Here, 100 000 iterations were used with a 10 000-iteration burn in for the MCMC parameter estimation. The statistical significance is indicated by Bayes factors, and the associated false discovery rates were calculated with a mixture model-based method of controlling the local FDR. The Qspec method also accounts for the length of the protein when determining the differential expression. Values reported are spectral counts for each protein calculated as average±SE of 3 biological replicates samples. All assigned spectra for each protein were used for spectral counting. Before statistical analysis, protein spectral counts were normalized using the Scaffold software (version3_00_02, Proteome Software Inc., Portland, OR) by calculating and averaging the number of identified spectra in each sample, then multiplying the number of spectra assigned to each protein by the ratio of the average spectral count:the number of total spectra in that sample. Protein ambiguity issues were handled using tools available in the Scaffold software. Only proteins identified with at least 2 unique peptides were included in the analysis. No outliers were removed.
Results
Proteomic Analysis
Human radial arteries macroscopically free of vascular disease were diced into small pieces and subjected to overnight incubation with MMP-3, MMP-9, or MMP-14 (100 ng MMP/mg tissue at 37°C plus proteinase inhibitors to inhibit proteinases other than MMPs). Radial arteries incubated in MMP buffer with or without EDTA served as control. The proteins released into the conditioned medium were concentrated and separated by SDS-PAGE. The entire lane was excised, subjected to ingel tryptic digestion, and analyzed by LC-MS/MS using a high-resolution mass spectrometer (LTQ Orbitrap XL, Thermo Fisher). All further analysis focused on 99 ECM or ECMrelated proteins (13 proteoglycans, 36 ECM glycoproteins, 14 collagens, 5 nonglycosylated ECM proteins, 19 other ECMassociated proteins, 12 proteases and protease inhibitors) identified with 95% peptide probability, 99% protein probability, 10 ppm mass accuracy, and a minimum of 2 peptides per protein (online-only Data Supplement Table I ). Three collagens (COSA1_HUMAN, COGA1_HUMAN, CO1A1_HUMAN) were only found when hydroxy-lysine and hydroxy-proline were chosen as variable modifications. All detected ECM and ECM-related proteins are listed in Table 1 .
Increased Release on Digestion by MMPs
Among the identified extracellular proteins, 25 proteins were differentially released on digestion by MMPs (Table 1) , including known MMP substrates like fibronectin (FINC), 9 collagens, 10 and perlecan (PGBM) 9, 11 (online-only Data Supplement Table II ) as well as unknown ones such as EMI-LIN-1 (EMIL1) and tenascin-X (TENX) ( Figure 1 ). For some MMP substrates, our study revealed release by additional MMPs, for example, CO6A3 by MMPs-3 and -9 (known substrate for MMP-2). 12 For others, for example, tenascin-C (TENA, known substrate for MMPs-3 and -14), statistical significance was obtained for MMP-3 but not for MMP-14. Protein fragments of small proteins, such as galectin-1 (LEG1), were migrating ahead of the gel front, thereby resulting in a reduced spectral count on digestion (Table 1 ). For independent validation of the proteomic findings, the samples were probed for fibronectin, galectin-1, tenascin-C, periostin, and tenascin-X by immunoblotting ( Figure 2 ). Indeed, immunoblots confirmed the degradation of galectin-1 by MMP-3 with the cleaved products close to the migration front on the SDS-PAGE. Consistent with the published literature, 13 degradation was also observed with MMP-9, but to a lesser extent. In contrast, we observed no cleavage with MMP-14. 14
Evidence for Protein Fragmentation
Proteolytic cleavage may occur without differential release into the conditioned medium, for example, for aggrecan (known substrate for MMPs-3, -9, -14) or nidogen-1 (known substrate for MMPs-3, -9, -14). Separation by SDS-PAGE before tryptic digestion preserves the native molecular weight of the protein.
Detailed examination of the gel-LC-MS/MS data revealed the presence of proteolytic products after incubation with MMPs: for aggrecan, nidogen-1, fibronectin, periostin, perlecan, tenascin-C, and tenascin-X, a high number of MS/MS spectra were identified in gel segments below the expected molecular weight of the native protein ( Figure 3 ). To further investigate MMPdependent proteolysis, additional specimens of radial arteries were incubated with 2 different concentrations of MMPs: 20 ng MMP/mg tissue (L-low) and 100 ng MMP/mg tissue (H-high) (Figure 4 , top). EDTA was added as negative control for inhibition of MMP activity (Figure 4 , bottom). In agreement with the proteomics findings and the published literature, 9, 15 fibronectin was degraded by MMPs-3 and -14 and to a lesser extent by MMP-9. Tenascin-X, a new substrate for MMPs, was cleaved by MMPs-3, -9, and -14. In contrast, tenascin-C was predominantly degraded by MMP-3 and to some extent by MMP-14 but not by MMP-9. This finding has been previously reported in the literature based on in vitro studies using purified proteins. 9, 16, 17 Our study provides the first evidence for cleavage of tenascin-C by MMPs-3 and -14 in human arterial tissue. Similarly, MMPs-3 and -14 cleaved periostin are another potential new substrate for both MMPs. As direct evidence, recombinant or purified fibronectin, tenascin-C, and periostin were incubated with MMPs-3, -9, and -14, and the cleavage products were analyzed by SDS-PAGE ( Figure 5A ). Fibronectin, a known substrate of MMPs, was cleaved by all 3 MMPs ( Figure 5B ). Tenascin-C ( Figure  5C ) and periostin ( Figure 5D ) were degraded by MMP-3.
Identification of Cleavage Sites
Next, all spectra were searched for nontryptic cleavages sites. Endogenous proteases, other than MMPs, were inhibited by addition of a proteinase inhibitor cocktail. Seventy-four semitryptic peptides (66 peptides were cleaved by MMP-3, 12 by MMP-9, and 12 by MMP-14) were identified in at least 2 of 3 radial arteries digested with MMPs but undetectable in controls ( Figure 6 , online-only Data Supplement Table III ). Two MMP cleavage sites were already known from the literature, 18 Figure  X) . In addition, we were able to detect 27 nontryptic cleavage sites in periostin (online-only Data Supplement Figure XI ) and 12 nontryptic cleavage sites for tenascin-C (online-only Data Supplement Figure XII) .
Evidence for Protein Degradation in Human Aortic Tissue
We have previously established a 3-step extraction procedure for the proteomic identification of ECM proteins in human thoracic aortas ( Figure 7A ). 21 In tissues, proteolytic degradation products are present in the NaCl fraction. As described, the different levels of endogenous MMP-9 activity ( Figure 7B ) were correlated to fibronectin degradation, a well-known substrate of MMP-9. When we reanalyzed this proteomics data set for evidence of degradation of novel candidate substrates identified by incubation with exogenous MMP-9 ( Figure 7C) , degradation was evident for collagen VI (CO6A3), collagen XV (COFA1), serum amyloid P-component (SAMP), and latent TGF-binding protein 2 (LTBP2) ( Figure 7D ). Fragmentation of collagen VI was independently confirmed by immunoblotting ( Figure 7E ).
Discussion
Proteolysis is a key mechanism to control ECM function during development and normal tissue turnover. To advance our understanding of ECM remodeling in disease, we have established proteomics methods to analyze the ECM composition in human aortas, 21 abdominal aortic aneurysms, 22 and after cardiac ischemia/reperfusion injury. 7 In these studies, the most abundant MMPs were detected, but a more detailed knowledge of their substrates is essential to link MMP activity to ECM changes in cardiovascular disease. Because MMPs do not hydrolyze peptide bonds in a sequence-specific manner, proteomics offers an opportunity for a comprehensive assessment of MMP substrates. 23, 24 
Degradomics
The degradome is the complete natural substrate repertoire of a protease in a cell, tissue, or organism. 25 Different MSbased approaches can be used for the identification of new MMP substrates and their cleavage sites, such as iCAT or iTRAQ, 26 label-free MS, 27 or 2-dimensional gel electrophoresis. 28 For the degradome of a certain subset of proteins, peptide libraries 29, 30 generate maps of potential cleavage sites for the protease of interest. Other proteomic approaches, such as TAILS, COFRADIC, and PROTOMAP, were developed for an enrichment and identification of new N-terminal peptides to identify specific protease cleavage sites. [31] [32] [33] A limitation of such in vitro approaches is the overestimation of the actual cleavage sites because certain proteins may be inaccessible to the protease in a tissue environment. In vivo studies on MMPs relied heavily on comparisons of cardiovascular phenotypes in transgenic and wild-type animals. 1 Potential caveats are that genetic manipulations frequently induce secondary changes. For example, List of all ECM proteins, ECM-related proteins, and collagens identified by proteomics. Values are the number of assigned spectra and are means±SD from 3 biological replicates. Statistical analyses were performed using the Qspec method described in Choi et al. The Bayes Factors (BR) were *** FDR≤0.001 and BF>10, ** FDR≤0.01 and BF>8, * FDR≤0.05 and BF>6 for differences vs control (−EDTA).
# Proteins that are known MMP substrates; for references see online-only Data Supplement Table II .
we have previously shown that aortas of apoE-deficient mice show low levels of ADAMTS-5 compared with wild-type controls. 34 This loss of ADAMTS-5 may be important for proteoglycan accumulation and lipoprotein retention. 35 Alterations in other proteases, however, complicate the interpretation of experiments with loss or gain of function for specific MMPs in apoE-deficient mice, and the clinical relevance of such findings should be further substantiated in human tissue.
Combined Ex Vivo/In Vivo Approach
Strengths of our study are the extensive proteomics analyses and the use of human arterial tissues: to identify MMP substrates, we compared the protein release from vascular tissues after incubation with 3 different MMPs. Evidence for protein fragmentation was collated from the gel-LC-MS/ MS experiment. Then mass spectra were searched for nontryptic peptides to identify MMP cleavage sites (online-only Data Supplement Table III ). For most candidate substrates, nontryptic peptides were detected, providing evidence that these proteins are indeed undergoing proteolytic cleavage on incubation with MMPs. As proof-of-principle, newly identified targets were confirmed by immunoblotting and digesting recombinant/purified proteins. Finally, our findings were related to human tissues with different levels of endogenous The log(fold change) for each of the differentially released proteins on digestion with MMPs is illustrated. The proteins are ordered from the smallest to largest false discovery rate (FDR) with significant differential expression set at a FDR<5%. The differential release and corresponding FDR was calculated using the Qspec method, which uses a model based on a hierarchical Bayes estimation of generalized linear mixed effects model (GLMM). The FDR, as per the Qspec method, was calculated using the Bayes factors and a mixture model-based method of controlling the local FDR. The Bayes factors (BR) were *** FDR≤0.001 and BF>10, ** FDR≤0.01 and BF>8, * FDR≤0.05 and BF>6. All protein identifications for ECM and ECM-related proteins are listed in Table 1 .
MMP activities, as reported for articular cartilage 18 and abdominal aortic aneurysms. 22 Novel candidate substrates identified by incubating arterial tissue with exogenous MMP-9 also displayed evidence for degradation in aortic tissues with high endogenous MMP-9 activity.
Novel MMP Substrates
MMP-3 but also MMP-9 cleaved numerous ECM proteins, predominantly in the basement membrane and the interstitial matrix. Among the basement membrane, proteins identified were collagen IV, XV, XVIII, nidogen, and perlecan (PGBM). Collagen XV (COFA1) was also degraded in aortic tissues with high MMP-9 activity. Collagen IV and perlecan are known MMP substrates (online-only Data Supplement  Table II ), but our study identified new cleavage sites. In all experiments, collagen VI consistently emerged as a novel substrate for MMP-9. Type VI collagen is 1 of the main components of interstitial matrix and particularly enriched in the pericellular matrix as well as the subendothelial matrix that binds von Willebrand factor and platelets. Collagen forming reticular fibers (collagen III) and proteins associated with elastic fibers (EMIL1 and LTBP2) were also detected. Elastic fibers are composed of the protein elastin and a network of microfibrils, consisting of several glycoproteins, including fibrillin-1, fibrillin-2, and microfibril-associated glycoproteins-1 and -2. 36 Notably, MMPs-3 and -9 degrade elastic fiber proteins, and damage to these structures can negatively affect the quality of the elastin network and impair vascular function. 37 Periostin and tenascins, in particular tenascin-X, were shown to be new MMP substrates. Tenascins are matricellular proteins that bind to ECM proteins and cell surface receptors without contributing to the structure of the ECM itself. Tenascin-X is an important regulator of collagen deposition by dermal fibroblasts. 38 In contrast, tenascin-C binds to fibronectin and inhibits cell spreading. 39 It is related to macrophage accumulation in vascular lesions, 40 increases the activity of MMPs, and is present in the vulnerable region of atherosclerotic plaques. The incorporation of tenascin-C into the ECM is promoted by periostin, 41 a 90-kDa secreted protein, which plays a role in vascular cell differentiation and migration. 42 We have previously identified periostin as a substrate of MMP-12. 22 This study demonstrates that periostin is also cleaved by MMP-3. Among the group of large aggregating proteoglycans, aggrecan was only recently detected in human arteries. 43 Our study now demonstrates its fragmentation on incubation with MMPs-3 and -9. 
Novel Cleavage Sites
For many known substrates, we identified potential new cleavage sites. Importantly, ECM fragments can have biological activity or contain biologically active sites that are not present or exposed in the original molecule. Such cryptic sites are known for some collagens (eg, endostatin, which inhibits endothelial cell proliferation and angiogenesis) 44 as well as fibronectin, 45 to name just a few. Fibronectin, for example, is 1 of the most prominent ECM proteins accumulating in atherosclerosis. The potential biological activity of the newly identified ECM fragments will have to be explored in future studies.
Limitations
Although a single MMP can have potent effects on the ECM, more complex processes involving the interplay of different MMPs and their inhibitors are taking place in vivo. This diminishes the power of tissue proteomics in identifying direct substrates of MMPs: It is known that MMPs can activate other MMPs, for example, MMP-3 activates MMP-9. 46 Thus, incubation with exogenous MMPs is likely to activate endogenous MMPs. This is impossible to overcome in human tissues, but all our buffers were supplemented with a proteinase inhibitor mixture to inhibit non-MMP proteinase activity. Proteins might be 
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S2 S3 S4 S1 S2 S3 S4 S1 S2 S3 S4 S1 S2 S3 S4 IB: Coll VI (α1-α2) released that were just bound to substrates of MMPs. So, the mere solubilization of proteins on digestion is insufficient to designate proteins as direct substrates of MMPs. Nonetheless, evidence of proteolytic degradation (Figures 3 and 5 ) and certain cleavage sites ( Figure 6 ) were independently observed in tissues as well as in recombinant/purified proteins. Finally, the analysis was filtered for extracellular proteins because arteries were snap-frozen after collection. Cells burst during the freezing process. Thus, interpreting the release of cellular proteins on digestion with MMPs would not be reliable.
Conclusion
This proteomics study provides a valuable resource for scientists investigating pathophysiological consequences of MMP activity. For the first time, it characterizes the overall effect of these important matrix-degrading enzymes in the human vasculature. Ultimately, such comparisons of different MMP activities may help to elucidate the mechanisms of plaque destabilization and aneurysm formation and identify new culprit molecules that could be targeted for therapy. 1, 47 
